VEGFA and glioblastoma: Glioblastomas are the most common and most aggressive form of primary brain tumors in adults.1 Patients with glioblastoma have a very poor prognosis because of the high propensity for relapse,2 with reported median survival times for patients with recurrent disease of just 3 to 9 months.3, 4 The angiogenic factor vascular endothelial growth factor (VEGF) is expressed at high levels in glioblastoma relative to other cancer types4; thus, inhibitors of VEGF have been investigated for the treatment of glioblastoma.5